
Opinion|Videos|July 22, 2024
Biologic Therapies for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.
Advertisement
Video content above is prompted by the following questions:
- What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
- Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
2
The Ongoing Debate Over E-Cigarettes and Public Health
3
FDA Approves CytoCell CDx for Revumenib in KMT2A-Mutant Acute Leukemia
4
Respiratory Health Risks Linked to Chemical Cleaners and Biomass Fuel in Homes
5